Cell Therapy Drug Product Development: Technical Considerations and Challenges

被引:4
|
作者
Weng, Lindong [1 ]
机构
[1] Novo Nordisk Res Ctr Seattle Inc, Seattle, WA 98109 USA
关键词
Cryopreservation; Controlled-rate freezer; Cryoprotectant; Formulation; Fill and finish; Stability; Dose preparation; CAR T; CRYOPRESERVATION;
D O I
10.1016/j.xphs.2023.08.001
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Cell therapy uses living cells as a drug to treat diseases. To develop a cell therapy drug product (DP), cryopreservation plays a central role in extending the shelf life of these living medicines by pausing their biological activities, especially preventing degradation, at a temperature as low as liquid nitrogen. This helps overcome the temporal and geographical gaps between centralized manufacturing and clinical administration, as well as allowing sufficient time for full release testing and flexibility in scheduling patients for administration. Cryopreservation determines or influences several key manufacturing, logistical, or clinical in-use processes, including formulation, filling, controlled rate freezing, cryogenic storage and transportation, thawing, and dose preparation. This article overviews the key technical aspects of cell therapy DP development and elucidates fundamental principles of cryobiology that should be considered when we design and optimize the relevant processes. This article also discusses the challenges that motivate continued innovation for cell therapy drug product development.(c) 2023 American Pharmacists Association. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:2615 / 2620
页数:6
相关论文
共 50 条
  • [1] Development of biosimilar drug product in prefilled syringe presentations: Considerations and challenges
    Jayaraman, Murali
    Sampathkumar, Krishnan
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2015, 249
  • [2] DEVELOPMENT OF DRUG RESIDUE IMMUNOASSAYS - TECHNICAL CONSIDERATIONS
    ORANGERS, JJ
    ACS SYMPOSIUM SERIES, 1990, 442 : 27 - 37
  • [3] Phage Therapy: Considerations and Challenges for Development
    Reindel, Rebecca
    Fiore, Cara R.
    CLINICAL INFECTIOUS DISEASES, 2017, 64 (11) : 1589 - 1590
  • [4] Considerations in T Cell Therapy Product Development for B Cell Leukemia and Lymphoma Immunotherapy
    Fesnak, Andrew D.
    Hanley, Patrick J.
    Levine, Bruce L.
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2017, 12 (04) : 335 - 343
  • [5] Considerations in T Cell Therapy Product Development for B Cell Leukemia and Lymphoma Immunotherapy
    Andrew D. Fesnak
    Patrick J. Hanley
    Bruce L. Levine
    Current Hematologic Malignancy Reports, 2017, 12 : 335 - 343
  • [6] Marine sponge aquaculture towards drug development: An ongoing history of technical, ecological, chemical considerations and challenges
    Maslin, Mathilde
    Gaertner-Mazouni, Nabila
    Debitus, Cecile
    de Voogd, Nicole Joy
    Ho, Raimana
    AQUACULTURE REPORTS, 2021, 21
  • [7] Challenges and Considerations of Preclinical Development for iPSC-Based Myogenic Cell Therapy
    Sun, Congshan
    Serra, Carlo
    Kalicharan, Brianna Harley
    Harding, Jeffrey
    Rao, Mahendra
    CELLS, 2024, 13 (07)
  • [8] Technical challenges in PEM fuel cell development
    Barbir, F
    HYDROGEN ENERGY PROGRESS XII, VOLS 1-3, 1998, : 1589 - 1596
  • [9] Challenges in Permeability Assessment for Oral Drug Product Development
    Koziolek, Mirko
    Augustijns, Patrick
    Berger, Constantin
    Cristofoletti, Rodrigo
    Dahlgren, David
    Keemink, Janneke
    Matsson, Paer
    McCartney, Fiona
    Metzger, Marco
    Mezler, Mario
    Niessen, Janis
    Polli, James E.
    Vertzoni, Maria
    Weitschies, Werner
    Dressman, Jennifer
    PHARMACEUTICS, 2023, 15 (10)
  • [10] ENVIRONMENTAL MONITORING CONSIDERATIONS FOR CELL THERAPY PRODUCT MANUFACTURING
    Wood, T.
    CYTOTHERAPY, 2015, 17 (06) : S30 - S31